Idorsia Drug Patent Portfolio
Idorsia owns 2 orange book drugs protected by 9 US patents Given below is the list of Idorsia's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11680058 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | 26 Jul, 2038 | Active |
| US11787782 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | 02 Mar, 2038 | Active |
| US10919881 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | 26 Feb, 2038 | Active |
| US12297189 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | 26 Feb, 2038 | Active |
| US11174247 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | 06 Nov, 2037 | Active |
| US10023560 | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist | 02 Dec, 2034 | Active |
| US9790208 | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist | 02 Dec, 2034 | Active |
| US9732075 | Benzimidazole-proline derivatives | 12 Jun, 2033 | Active |
| US8324232 | 4-pyrimidinesulfamide derivative | 21 Sep, 2029 | Active |
Latest Legal Activities on Idorsia's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Idorsia.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification | 17 Sep, 2025 | US11680058 |
| Mail Patent eCofC Notification | 16 Sep, 2025 | US11680058 |
| Patent eCofC Notification | 16 Sep, 2025 | US11680058 |
| Recordation of Patent eCertificate of Correction | 16 Sep, 2025 | US11680058 |
| Mail Certificate of Correction Memo | 25 Aug, 2025 | US11680058 |
| Post Issue Communication - Certificate of Correction | 25 Aug, 2025 | US11680058 |
| Certificate of Correction Memo | 21 Aug, 2025 | US11680058 |
| Second letter to regulating agency to determine regulatory review period | 19 Aug, 2025 | US8324232 |
| Letter from FDA or Dept of Agriculture re PTE application | 12 Aug, 2025 | US8324232 |
| Information Disclosure Statement (IDS) Filed | 12 Aug, 2025 | US8324232 |
| Terminal Disclaimer Filed | 08 Aug, 2025 | US9732075 |
| PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED | 08 Aug, 2025 | US9732075 |
| Notice of Final Determination -Eligible | 08 Jul, 2025 | US9732075 |
| FDA Final Eligibility Letter | 20 May, 2025 | US9732075 |
| Recordation of Patent Grant Mailed | 20 May, 2025 | US12297189 |
Idorsia's Family Patents
Idorsia Drug List
Given below is the complete list of Idorsia's drugs and the patents protecting them.
1. Quviviq
Quviviq is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10023560 | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
02 Dec, 2034
(8 years from now)
| Active |
| US9790208 | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
02 Dec, 2034
(8 years from now)
| Active |
| US9732075 | Benzimidazole-proline derivatives |
12 Jun, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Quviviq's drug page
2. Tryvio
Tryvio is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11680058 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
26 Jul, 2038
(12 years from now)
| Active |
| US11787782 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
02 Mar, 2038
(11 years from now)
| Active |
| US10919881 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
26 Feb, 2038
(11 years from now)
| Active |
| US12297189 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
26 Feb, 2038
(11 years from now)
| Active |
| US11174247 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
06 Nov, 2037
(11 years from now)
| Active |
| US8324232 | 4-pyrimidinesulfamide derivative |
21 Sep, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tryvio's drug page